Edition:
United States

Pharmaxis Ltd (PXS.AX)

PXS.AX on Australia Stock Exchange

0.28AUD
--
Change (% chg)

-- (--)
Prev Close
$0.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
495,100
52-wk High
$0.34
52-wk Low
$0.25

Latest Key Developments (Source: Significant Developments)

Pharmaxis appoints Chiesi as Bronchitol distributor in Italy
Sunday, 7 May 2017 11:49pm EDT 

May 8 (Reuters) - Pharmaxis Ltd :Pharmaxis appoints Chiesi as Bronchitol distributor in Italy.Entered into an exclusive distribution and supply agreement with Chiesi Farmaceutici Spa.  Full Article

Synairgen announces additional positive data from LOXL2 inhibitor programme
Friday, 10 Mar 2017 03:34am EST 

Synairgen Plc : Additional positive data in lung fibrosis . Oral administration of one of the compounds significantly inhibited cross-link formation, reduced fibrosis score and improved lung function . Successful completion of toxicology studies will enable commencement of phase I clinical trials in h2 this year as planned . Expect to commence phase I clinical trials of LOXL2 inhibitor during second half of 2017 .Expect to hear outcome of Astrazeneca phase II trial of interferon beta during first half of 2017.  Full Article

Synairgen Plc announces research collaboration with Pharmaxis Ltd
Wednesday, 5 Aug 2015 02:01am EDT 

Synairgen Plc and Pharmaxis Ltd:Entered into research collaboration to develop selective inhibitor to lysyl oxidase type 2 enzyme (LOXL2) to treat fatal lung disease idiopathic pulmonary fibrosis (IPF).IPF affects in region of 100,000 people in US.Current products are expected to produce global revenues in excess of $1.1 bln by 2017.Says LOXL2 enzyme is being targeted because it is known to promote scar tissue which hardens and irreparably damages lungs of IPF patients.It is hoped that inhibition of LOXL2 will slow build-up of scar tissue and improve survival rates that are worse than for many cancers.  Full Article

Pharmaxis announces research collaboration with Synairgen
Tuesday, 4 Aug 2015 08:09pm EDT 

Pharmaxis Ltd:Pharmaxis and Synairgen announces research collaboration to develop loxl2 inhibitor for Pulmonary Fibrosis.  Full Article

More From Around the Web

BRIEF-Pharmaxis says Boehringer confirms phase 2 study for second disease indication will commence this year

* In addition to a phase 2 trial in Nash that is scheduled to start mid‐year, Boehringer has confirmed that a phase 2 study for a second disease indication will commence this year Source text for Eikon: Further company coverage: